Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) shares traded up 3.1% on Friday . The stock traded as high as $0.9283 and last traded at $0.9283. Approximately 100 shares were traded during trading, a decline of 100% from the average daily volume of 26,123 shares. The stock had previously closed at $0.90.
Avacta Group Stock Up 3.1%
The stock has a fifty day moving average of $0.96 and a 200-day moving average of $0.94.
Avacta Group Company Profile
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
See Also
- Five stocks we like better than Avacta Group
- Travel + Leisure Goes Big—Is It Ready to Rally?
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
